Quantcast

Latest Dextroamphetamine Stories

2014-09-15 08:29:16

PHILADELPHIA, September 15, 2014 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPG), the global specialty biopharmaceutical company, announced today that the US Food and Drug Administration (FDA) has accepted for filing with priority review a supplemental New Drug Application (sNDA) for Vyvanse(R) (lisdexamfetamine dimesylate) Capsules (CII) as a treatment for adults with binge eating disorder (BED). The FDA is expected to provide a decision in February 2015, based on the...

2014-07-17 16:25:39

LEXINGTON, Massachusetts, July 17, 2014 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPG) today announced top-line results from two Phase 4 efficacy and safety studies of Vyvanse(R) (lisdexamfetamine dimesylate) compared with Concerta (methylphenidate HCl) with a placebo reference arm in adolescents aged 13-17 diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD). In SPD489-406, the forced-dose titration study, Vyvanse was found to be statistically superior to...

2014-06-25 04:20:59

LEXINGTON, Massachusetts, June 25, 2014 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPG) announces that Judge Stanley R. Chesler of the U.S. District Court for the District of New Jersey granted Shire's summary judgment motion in a patent infringement lawsuit, holding that certain claims of the patents protecting Vyvanse(R) (lisdexamfetamine dimesylate) were both infringed and valid. The ruling prevents the five pharmaceutical manufacturers (the ANDA Defendants) who...

2014-06-04 12:30:28

MIDDLESEX, N.J., June 4, 2014 /PRNewswire/ -- CorePharma, LLC ("CorePharma"), a developer, manufacturer, and marketer of targeted generic prescription pharmaceuticals, announced today that it has launched Dextroamphetamine Sulfate Tablets, USP ("Dextroamphetamine"), the generic version of Shire's Dextrostat®. Dextroamphetamine is indicated for the treatment of narcolepsy and attention deficit disorder with hyperactivity. CorePharma received final approval from the U.S. Food and Drug...

2014-04-28 08:32:18

TORONTO, April 28, 2014 /PRNewswire/ - Highland Therapeutics Inc. ("Highland"), an emerging pharmaceutical company, today announced that its wholly owned subsidiary has begun enrolment in a Phase III study of HLD-200, the Company's novel formulation of methylphenidate, in pediatric patients with Attention-Deficit Hyperactivity Disorder ("ADHD"). The study, "A Phase III Clinical Endpoint Evaluation Study ("CEES") Examining the Safety and Efficacy of HLD-200 in Pediatric Subjects with...

2014-04-08 10:48:49

Genetic variants associated with enjoying the effects of d-amphetamine—the active ingredient in Adderall—are also associated with a reduced risk for developing schizophrenia and attention deficit hyperactivity disorder (ADHD), report scientists from the University of Chicago in the Proceedings of the National Academy of Sciences on April 7. The results support a long-standing hypothesis that dopamine, the neurotransmitter connected with the euphoric effects of amphetamine, is related to...

2014-04-07 12:33:42

Contest for adults who struggle with organization PHILADELPHIA, April 7, 2014 /PRNewswire/ -- Shire today announced the launch of the Organize Your Stuff contest, which is designed for adults who want help organizing their space and reducing clutter. The contest includes the support of expert organizer Monica Friel, president and founder of Chaos to Order, a respected professional organizing service. To enter, adults ages 18 and over can submit a photo to OrganizeYourStuffContest.com. The...

2014-02-25 08:32:17

TORONTO, Feb. 25, 2014 /PRNewswire/ - Highland Therapeutics Inc. ("Highland"), an emerging pharmaceutical company, today announced that the Company's President and Chief Executive Officer, David Lickrish, will present at the 34(th) Annual Cowen and Company Health Care Conference at the Boston Marriott Copley Place in Boston, MA. Highland's presentation is scheduled for Monday, March 3, 2014 at 11:00am EST. A live webcast of the presentation can be accessed by visiting...

2014-02-06 16:28:08

DUBLIN, February 6, 2014 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPG) announces top-line results from two pivotal Phase 3 investigational studies evaluating the efficacy and safety of Vyvanse(R) (lisdexamfetamine dimesylate) Capsules (CII) versus placebo as an adjunctive treatment for major depressive disorder (MDD) in adults who inadequately responded to antidepressant monotherapy with a SSRI or SNRI. Vyvanse did not meet the primary efficacy endpoint versus placebo for...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related